Pregled bibliografske jedinice broj: 1134522
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Once-Weekly Semaglutide in Adults with Overweight or Obesity // New England Journal of Medicine, 385 (2021), 1; 4-4 doi:10.1056/nejmc2106918 (međunarodna recenzija, pismo, znanstveni)
CROSBI ID: 1134522 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Once-Weekly Semaglutide in Adults with Overweight or
Obesity
Autori
Javor, Eugen ; Lucijanić, Marko ; Skelin, Marko
Izvornik
New England Journal of Medicine (0028-4793) 385
(2021), 1;
4-4
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo, znanstveni
Ključne riječi
glucagon-like peptide-1 (GLP-1) analogues ; semaglutide ; hypoglycemia
Sažetak
The risk of hypoglycemia in patients who are receiving glucagon-like peptide-1 (GLP-1) analogues as monotherapy is considered to be insignificant. In the recent phase 3 Semaglutide Treatment Effect in People with Obesity 1 (STEP 1) trial by Wilding et al. (March 18 issue), 1 the incidence of hypoglycemia that was associated with the GLP-1 analogue semaglutide was only 0.6% in adults with overweight or obesity. However, in a similar trial of another GLP-1 analogue (liraglutide), 2 investigators found a higher incidence of hypoglycemia with liraglutide than with placebo (11.9% vs. 3.3%). In that trial, the majority of cases of . . .
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti, Farmacija
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Opća bolnica Šibenik,
Klinička bolnica "Dubrava"
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
